This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

DaVita To Present Twelve Posters And One Oral Presentation At American Society Of Nephrology Kidney Week

DaVita Inc. (NYSE: DVA), a leading provider of kidney care services committed to improving the quality of life for those diagnosed with chronic kidney disease (CKD), will present 13 abstracts at the American Society of Nephrology (ASN) Kidney Week in San Diego, November 1-4. Attendees can find DaVita® representatives in booth #1903.

ASN’s annual Kidney Week provides a valuable opportunity for more than 13,000 kidney care professionals from around the world to share and discuss new developments related to all aspects of nephrology.

“Our goal at DaVita – in collaboration with our partners – is to advance the knowledge and practice of kidney care,” said DaVita Vice President of DaVita Clinical Research® Mahesh Krishnan. “The work we will share at ASN will, we hope, lead to better clinical outcomes and better quality of life for CKD and end-stage renal disease patients around the world.”

Researchers from DaVita and DaVita Clinical Research (DCR®) will present results from a number of innovative clinical improvement programs and health economic studies originating from DaVita and its research partners. DCR provides a collaborative bridge between DaVita services and the academic, pharmaceutical, and biotech research community. DCR shares DaVita’s dedication to improving the health and quality of life for kidney patients.

ASN Kidney Week abstract highlights include the following:
  • Extracellular Volume Control in Dialysis Patients To Reduce Hospitalizations (oral presentation FR-OR026 of joint study between DaVita, Fresenius Medical Care, and Renal Ventures, LLL; to be presented by Thomas Parker, M.D., Renal Ventures Management, LLC)
  • Analysis of the 2014 Quality Improvement Program Reporting Measures for Calcium Phosphate in Dialysis Patients (Nissenson et al, abstract SA-PO268)
  • Hemoglobin Trends in Incident End-Stage Renal Disease (ESRD) Patients from 2008-2011 (Weldon et al, abstract FR-PO222)
  • Changing Hemoglobin Targets: Effects on Epoetin Alfa, Intravenous Iron, and Iron Storage Measures From 2009–2012 (Bond et al, abstract TH-PO822)
  • A Comparative Analysis of Transfusion Trends between Types of Providers of Dialysis Services Using Medicare Claims Data (Krishnan et al, abstract FR-PO263)

DaVita, DaVita Clinical Research and DCR registered trademarks of DaVita Inc. All other trademarks are the property of their respective owners.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,081.89 -49.97 -0.29%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,796.6090 -42.0340 -0.87%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs